|
Valeant Canada is actively seeking to
in-license late-stage clinical and/or
commercialized products in the following
key disease target areas.
Neurology
|
Dermatology
|
Specialty
|
|
|
|
|
- Pain Management
- Parkinson’s Disease
- Epilepsy
- Multiple Sclerosis
- Huntington’s Disease
- ALS
|
- Psoriasis
- Eczema
- Acne
- Rosacea
- Actinic Keratoses
- Squamous Cell Carcinoma
-
Anti-fungals (topical)
|
|
Valeant’s Collaboration Process
When a product is evaluated at Valeant it passes through five inter-related stages. As an integrated pharmaceutical
organization Valeant’s management team is capable of gathering robust information and resources to efficiently come to
decisions promptly and to advance the collaboration process into the launch stage.
|
